Search

This study aimed to investigate the differences in complications between hepatitis B virus (HBV)-related and alcohol-related cirrhoses.

C10H16N12O6S2, triclinic, P1‾ $P\overline{1}$ (no. 2), a = 7.6977(2) Å, b = 11.5353(3) Å, c = 11.7533(3) Å, α = 67.973(2)°, β = 87.916(2)°, γ = 88.347(2)°, V = 966.69(5) Å3, Z = 2, R gt(F) = 0.0290, wR ref(F 2) = 0.0818, T = 170K.

C23H39ClN2O4, triclinic, P1‾$P‾{1}$ (no. 2), a = 9.0752(19) Å, b = 9.542(2) Å, c = 16.049(3) Å, α = 99.088(4)°, β = 94.422(4)°, γ = 107.146(4)°, V = 1300.0(5) Å3, Z = 2, Rgt(F) = 0.0646, wRref(F2) = 0.2298, T = 293.0 K.

C24H34N6Cl2Zn, monoclinic, P21/c (no. 14), a = 9.513(3) Å, b = 9.546(3) Å, c = 30.956(10) Å, β = 101.228(9)°, V = 2757.3(15) Å3, Z = 4, Rgt(F) = 0.0452, wRref(F2) = 0.1299, T = 293 K.

C39H37CuFeOP2S2, triclinic, P1̄ (no. 2), a = 9.6132(10) Å, b = 11.5667(12) Å, c = 16.8739(18) Å, α = 99.732(2)°, β = 96.342(2)°, γ = 93.446(2)°, V = 1832.0(3) Å3, Z = 2, Rgt(F) = 0.0455, wRref(F2) = 0.1212, T = 293.0 K.

C44H56N10S2O6Ni, triclinic, P1̄ (no. 2), a = 9.3077(14) Å, b = 9.9624(14) Å, c = 14.0449(19) Å, α = 70.889(3)°, β = 75.532(2)°, γ = 87.544(3)°, V = 1190.5(3) Å3, Z = 1, Rgt(F) = 0.0528, wRref(F2) = 0.1279, T = 293 K.

C26H20N10O6S2Pb, triclinic, P1̄ (no. 2), a = 9.3480(19) Å, b = 12.985(3) Å, c = 14.278(3) Å, α = 113.14(3)°, β = 92.05(3)°, γ = 102.75(3)°, V = 1539.8(7) Å3, Z = 2, Rgt(F) = 0.0336, wRref(F2) = 0.0874, T = 293.0 K.

C10H16N6O3, monoclinic, P21/c$P{2}_{1}/c$ (no. 14), a = 7.2312(1) Å, b = 17.7721(3) Å, c = 11.0146(2) Å, β = 104.557°, V = 1370.08(4) Å3, Z = 4, Rgt (F) = 0.0532, wRref (F2) = 0.1537, T = 170.0 K.

C6H12N6O4, monoclinic, P21/n (no. 14), a = 7.3652(3) Å, b = 16.8683(7) Å, c = 8.3779(3) Å, β = 101.525(4)°, V = 1019.87(7) Å3, Z = 4, Rgt(F) = 0.0349, wRref(F2) = 0.1018, T = 170 K.

C22H28Cl2N4Ni, monoclinic, P21/c (no. 14), a = 9.7332(19) Å, b = 14.886(3) Å, c = 18.623(5) Å, β = 117.45(2)°, V = 2394.5(10) Å3, Z = 4, Rgt(F) = 0.0450, wRref(F2) = 0.1466, T = 293.0 K.

C16H24O6, triclinic, P1̄ (no. 2), a = 6.3410(13) Å, b = 7.3430(15) Å, c = 10.241(2) Å, α = 94.06(3)°, β = 103.89(3)°, γ = 113.13(3)°, V = 418.3(8) Å3, Z = 1, Rgt(F) = 0.0546, wRref(F2) = 0.1691, T = 295(3) K.

C18H26N4NiO4, triclinic, P1̄ (no. 2), a = 7.7547(16) Å, b = 7.8666(16) Å, c = 8.2798(17) Å, α = 90.46(3)°, β = 96.24(3)°, γ = 93.25(3)°, V = 501.24(18) Å3, Z = 1, Rgt(F) = 0.0294, wRref(F2) = 0.0873, T = 310 K.

C17H14N2OFCl, triclinic, P1̄ (no. 2), a = 8.2387(19) Å, b = 9.764(2) Å, c = 10.644(3) Å, α = 72.023(4)°, β = 72.770(4)°, γ = 78.581(4)°, V = 772.5(3) Å3, Z = 2, Rgt(F) = 0.0444, wRref(F2) = 0.1099, T = 294.15 K.

C10H16N12O6S2, triclinic, P 1 ‾ $P\overline{1}$ (no. 2), a = 7.6977(2) Å, b = 11.5353(3) Å, c = 11.7533(3) Å, α = 67.973(2)°, β = 87.916(2)°, γ = 88.347(2)°, V = 966.69(5) Å3, Z = 2, Rgt(F) = 0.0290, wRref(F2) = 0.0818, T = 170K. [ABSTRACT FROM AUTHOR]

C10H16N12O6S2, triclinic, P 1 ‾ $P\overline{1}$ (no. 2), a = 7.6977(2) Å, b = 11.5353(3) Å, c = 11.7533(3) Å, α = 67.973(2)°, β = 87.916(2)°, γ = 88.347(2)°, V = 966.69(5) Å3, Z = 2, Rgt(F) = 0.0290, wRref(F2) = 0.0818, T = 170K. [ABSTRACT FROM AUTHOR]

The Nm23 gene has been acknowledged to play a crucial role in lung cancer metastasis inhibitory cascades controlled by multiple factors. Low expression or allelic deletion of nm23-H1 is strongly linked to widespread metastasis and poor differentiation of non-small cell lung cancer (NSCLC). In this study, nm23-H1 was down regulated in epithelial-mesenchymal transition (EMT) and stemness enhancement under cobalt chloride (CoCl2)-induced hypoxia in NSCLC cells. Moreover, knocking down of nm23-H1 by shRNA apparently promoted hypoxia induced EMT and stemness, which was entirely suppressed via over expression of nm23-H1. Mechanistically, the Wnt/β-catenin signaling pathway was found to participate in the nm23-H1-mediated process. Besides, XAV939 prohibited cell EMT and stemness which could be impaired by knocking down of nm23-H1, while stable transfection of nm23-H1 attenuated hypoxia phonotype induced by lithium chloride (LiCl). Generally, our experiment provided evidence that nm23-H1 can reverse hypoxia induced EMT and stemness through the inhibition of the Wnt/β-catenin pathway, which may furnish a deeper perspective into the better treatment or prognosis for NSCLC. [ABSTRACT FROM AUTHOR]

C23H39ClN2O4, triclinic, P1 (no. 2), a = 9.0752(19) Å, b = 9.542(2) Å, c = 16.049(3) Å, α = 99.088(4)°, β = 94.422(4)°, γ = 107.146(4)°, V = 1300.0(5) Å3, Z = 2, Rgt(F) = 0.0646, wRref(F2) = 0.2298, T = 293.0 K. [ABSTRACT FROM AUTHOR]

C24H34N6Cl2Zn, monoclinic, P21/c (no. 14), a = 9.513(3) Å, b = 9.546(3) Å, c = 30.956(10) Å, β = 101.228(9)°, V = 2757.3(15) Å3, Z = 4, Rgt(F) = 0.0452, wRref(F2) = 0.1299, T = 293 K. [ABSTRACT FROM AUTHOR]

C23H39ClN2O4, triclinic, P1 (no. 2), a = 9.0752(19) Å, b = 9.542(2) Å, c = 16.049(3) Å, α = 99.088(4)°, β = 94.422(4)°, γ = 107.146(4)°, V = 1300.0(5) Å3, Z = 2, Rgt(F) = 0.0646, wRref(F2) = 0.2298, T = 293.0 K. [ABSTRACT FROM AUTHOR]

C39H37CuFeOP2S2, triclinic, P1̄ (no. 2), a = 9.6132(10) Å, b = 11.5667(12) Å, c = 16.8739(18) Å, α = 99.732(2)°, β = 96.342(2)°, γ = 93.446(2)°, V = 1832.0(3) Å3, Z = 2, Rgt(F) = 0.0455, wRref(F2) = 0.1212, T = 293.0 K. [ABSTRACT FROM AUTHOR]

C26H20N10O6S2Pb, triclinic, P1̄ (no. 2), a = 9.3480(19) Å, b = 12.985(3) Å, c = 14.278(3) Å, α = 113.14(3)°, β = 92.05(3)°, γ = 102.75(3)°, V = 1539.8(7) Å3, Z = 2, Rgt(F) = 0.0336, wRref(F2) = 0.0874, T = 293.0 K. [ABSTRACT FROM AUTHOR]

C44H56N10S2O6Ni, triclinic, P1̄ (no. 2), a = 9.3077(14) Å, b = 9.9624(14) Å, c = 14.0449(19) Å, α = 70.889(3)°, β = 75.532(2)°, γ = 87.544(3)°, V = 1190.5(3) Å3, Z = 1, Rgt(F) = 0.0528, wRref(F2) = 0.1279, T = 293 K. [ABSTRACT FROM AUTHOR]

C10H16N10O6, monoclinic, C2/c (no. 15), a = 12.5131(7) Å, b = 16.4675(9) Å, c = 8.1488(4) Å,β = 107.361(5)°, V = 1602.64(15) Å3, Z = 4, Rgt(F) = 0.0380, wRref(F2) = 0.1180, T = 170(1) K. [ABSTRACT FROM AUTHOR]

C6H12N6O4, monoclinic, P21/n (no. 14), a = 7.3652(3) Å, b = 16.8683(7) Å, c = 8.3779(3) Å, β = 101.525(4)°, V = 1019.87(7) Å3, Z = 4, Rgt(F) = 0.0349, wRref(F2) = 0.1018, T = 170 K. [ABSTRACT FROM AUTHOR]

C10H16N6O3, monoclinic, P21/c (no. 14), a = 7.2312(1) Å, b = 17.7721(3) Å, c = 11.0146(2) Å, β = 104.557°, V = 1370.08(4) Å3, Z = 4, Rgt (F) = 0.0532, wRref (F2) = 0.1537, T = 170.0 K. [ABSTRACT FROM AUTHOR]

C14H20O6, triclinic, P1̄ (no. 2), a = 6.4270(13) Å, b = 8.3458(17) Å, c = 8.4120(17) Å, α = 107.08(3)°, β = 106.43(3)°, γ = 107.37(3)°, V = 376.2(2) Å3, Z = 1, Rgt(F) = 0.0521, wRref(F2) = 0.1541, T = 294.0 K. [ABSTRACT FROM AUTHOR]

C16H24O6, triclinic, P1̄ (no. 2), a = 6.3410(13) Å, b = 7.3430(15) Å, c = 10.241(2) Å, α = 94.06(3)°, β = 103.89(3)°, γ = 113.13(3)°, V = 418.3(8) Å3, Z = 1, Rgt(F) = 0.0546, wRref(F2) = 0.1691, T = 295(3) K. [ABSTRACT FROM AUTHOR]

Copyright of Zeitschrift für Kristallographie / New Crystal Structures is the property of De Gruyter and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Zeitschrift für Kristallographie / New Crystal Structures is the property of De Gruyter and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

C18H28O6, monoclinic, C2/c (no. 15), a = 15.061(3) Å, b = 13.791(3) Å, c = 10.106(2) Å, β = 118.60(3)°, V = 1843.0(8) Å3, Z = 4, Rgt(F) = 0.0462, wRref(F2) = 0.1315, T = 294.3 K. [ABSTRACT FROM AUTHOR]

C18H28O6, monoclinic, C2/c (no. 15), a = 15.061(3) Å, b = 13.791(3) Å, c = 10.106(2) Å, β = 118.60(3)°, V = 1843.0(8) Å3, Z = 4, Rgt(F) = 0.0462, wRref(F2) = 0.1315, T = 294.3 K. [ABSTRACT FROM AUTHOR]

C18H26N4NiO4, triclinic, P1̄ (no. 2), a = 7.7547(16) Å, b = 7.8666(16) Å, c = 8.2798(17) Å, α = 90.46(3)°, β = 96.24(3)°, γ = 93.25(3)°, V = 501.24(18) Å3, Z = 1, Rgt(F) = 0.0294, wRref(F2) = 0.0873, T = 310 K. [ABSTRACT FROM AUTHOR]

C18H26N4NiO4, triclinic, P1̄ (no. 2), a = 7.7547(16) Å, b = 7.8666(16) Å, c = 8.2798(17) Å, α = 90.46(3)°, β = 96.24(3)°, γ = 93.25(3)°, V = 501.24(18) Å3, Z = 1, Rgt(F) = 0.0294, wRref(F2) = 0.0873, T = 310 K. [ABSTRACT FROM AUTHOR]

C17H14N2OFCl, triclinic, P1̄ (no. 2), a = 8.2387(19) Å, b = 9.764(2) Å, c = 10.644(3) Å, α = 72.023(4)°, β = 72.770(4)°, γ = 78.581(4)°, V = 772.5(3) Å3, Z = 2, Rgt(F) = 0.0444, wRref(F2) = 0.1099, T = 294.15 K. [ABSTRACT FROM AUTHOR]

C6H12N6O4, monoclinic, P21/n (no. 14), a = 7.3652(3) Å, b = 16.8683(7) Å, c = 8.3779(3) Å, β = 101.525(4)°, V = 1019.87(7) Å3, Z = 4, Rgt(F) = 0.0349, wRref(F2) = 0.1018, T = 170 K. [ABSTRACT FROM AUTHOR]

C10H16N12O6S2, triclinic, P 1 ‾ $P\overline{1}$ (no. 2), a = 7.6977(2) Å, b = 11.5353(3) Å, c = 11.7533(3) Å, α = 67.973(2)°, β = 87.916(2)°, γ = 88.347(2)°, V = 966.69(5) Å3, Z = 2, Rgt(F) = 0.0290, wRref(F2) = 0.0818, T = 170K. [ABSTRACT FROM AUTHOR]

C10H16N12O6S2, triclinic, P 1 ‾ $P\overline{1}$ (no. 2), a = 7.6977(2) Å, b = 11.5353(3) Å, c = 11.7533(3) Å, α = 67.973(2)°, β = 87.916(2)°, γ = 88.347(2)°, V = 966.69(5) Å3, Z = 2, Rgt(F) = 0.0290, wRref(F2) = 0.0818, T = 170K. [ABSTRACT FROM AUTHOR]

C10H16N10O6, monoclinic, C2/c (no. 15), a = 12.5131(7) Å, b = 16.4675(9) Å, c = 8.1488(4) Å,β = 107.361(5)°, V = 1602.64(15) Å3, Z = 4, Rgt(F) = 0.0380, wRref(F2) = 0.1180, T = 170(1) K. [ABSTRACT FROM AUTHOR]

C10H16N6O3, monoclinic, P21/c (no. 14), a = 7.2312(1) Å, b = 17.7721(3) Å, c = 11.0146(2) Å, β = 104.557°, V = 1370.08(4) Å3, Z = 4, Rgt (F) = 0.0532, wRref (F2) = 0.1537, T = 170.0 K. [ABSTRACT FROM AUTHOR]